title: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
abstract: BACKGROUND
  Surgery is a curative treatment for patients with locally advanced colon cancer, but recurrences are frequent for those with stage III disease. FOLFOX adjuvant chemotherapy has been shown to improve recurrence-free survival and overall survival by more than 20% and is nowadays considered a standard of care. However, the vast majority of patients will not benefit from receiving cytotoxic drugs because they have either already been cured by surgery or because their tumor cells are resistant to the chemotherapy, for which predictive factors are still not available.
  
  
  METHODS
  PePiTA is a prospective, multicenter, non-randomised trial built on the hypothesis that preoperative chemosensitivity testing using FDG-PET/CT before and after one course of FOLFOX can identify the patients who are unlikely to benefit from 6 months of adjuvant FOLFOX treatment for stage III colon cancer.
  
  
  CONCLUSIONS
  PePiTA is the first study to use the primitive tumor chemosensitivity assessed by metabolic imaging as a guidance for adjuvant therapy in colon cancer. It could pave the way for tailoring the treatment and avoiding useless toxicities for the patients and inadequate expenses for the society. It could also give an interesting insight into tumoral heterogeneity, resistance to chemotherapy, genetic predisposants to oxaliplatin toxicity and immune response to cancer.
  2009-011445-13 TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00994864.
authors.forename: Alain
authors.initials: A
authors.lastname: Hendlisz
authors.forename: Vassilis
authors.initials: V
authors.lastname: Golfinopoulos
authors.forename: Amelie
authors.initials: A
authors.lastname: Deleporte
authors.forename: Marianne
authors.initials: M
authors.lastname: Paesmans
authors.forename: Hazem El
authors.initials: HE
authors.lastname: Mansy
authors.forename: Camilo
authors.initials: C
authors.lastname: Garcia
authors.forename: Marc
authors.initials: M
authors.lastname: Peeters
authors.forename: Lieven
authors.initials: L
authors.lastname: Annemans
authors.forename: Caroline
authors.initials: C
authors.lastname: Vandeputte
authors.forename: Marion
authors.initials: M
authors.lastname: Maetens
authors.forename: Ivan
authors.initials: I
authors.lastname: Borbath
authors.forename: Damien
authors.initials: D
authors.lastname: Dresse
authors.forename: Ghislain
authors.initials: G
authors.lastname: Houbiers
authors.forename: Michael
authors.initials: M
authors.lastname: Fried
authors.forename: Ahmad
authors.initials: A
authors.lastname: Awada
authors.forename: Martine
authors.initials: M
authors.lastname: Piccart
authors.forename: Jean-Luc Van
authors.initials: JL
authors.lastname: Laethem
authors.forename: Patrick
authors.initials: P
authors.lastname: Flamen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001530:Belgium; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D015321:Gene Rearrangement; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D049268:Positron-Emission Tomography; D011300:Preoperative Care; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil